Insights
Search Results
Blog Posts
10.20.26
Corp Fin Issues New and Revised CFIs on Use of Form S-8, Rule 701, and Form 4 Deadlines
The SEC’s Division of Corporation Finance recently published six new and two revised Corporation Finance Interpretations (CFIs) addressing the registration of stock underlying equity compensation awards and benefit plans. Collectively, the CFIs ease several longstanding staff positions on the timing of Form S-8 registration for restricted stock and restricted stock units, the treatment of awards assumed from acquired companies, and awards granted prior to an initial public offering.
Client Highlights
10.19.26
Firm Advises Alector on $75 Million Underwritten Offering
On October 16, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock at an offering price of $2.05 per share, which represents a premium of approximately 7.3 percent over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000 before deducting the underwriting discounts and commissions and other estimated offering expenses. The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
10.16.26
Wilson Sonsini Advises Amaero on IPO
On October 14, 2026, Amaero, a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing (AM) and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing (PM-HIP) manufacturing of large near-net-shape components, announced the pricing of its initial public offering of 4,705,883 shares of its common stock at a price of $4.25 per share. Amaero has also granted the underwriters a 30-day option to purchase up to an additional 705,882 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. Wilson Sonsini Goodrich & Rosati advised Amaero on the transaction.
Client Highlights
10.16.26
Wilson Sonsini Advises Iambic Therapeutics on $150 Million Initial Public Offering
Wilson Sonsini advised Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, in connection with the company’s $150 million initial public offering (IPO). Iambic issued 9,375,000 shares of its common stock at a public offering price of $16 per share, with a 30-day option for the underwriters to purchase up to an additional 1,406,250 shares. Iambic’s common stock began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.”
Client Highlights
10.16.26
Wilson Sonsini Advises Recursion on $200 Million Follow-On Offering
On October 16, 2026, Recursion Pharmaceuticals, a clinical-stage company using AI-enabled drug discovery and development, closed an underwritten public offering of 61,540,000 shares of its Class A common stock at a public offering price of $3.25 per share. The gross proceeds from the offering were approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Newsletters
9.28.26
2026 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini is pleased to present the 2026 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Newsletters
9.22.26
2026 Mid-Year Technology and Life Sciences IPO Report
Wilson Sonsini's 2026 Mid-Year Technology and Life Sciences IPO Report presents in-depth analysis related to 37 initial public offerings (IPOs) with deal values exceeding $75 million or direct listings completed by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Client Highlights
9.10.26
Wilson Sonsini Advises Autodesk on $1 Billion Senior Notes Offering
On September 10, 2026, Autodesk, Inc., completed its offering of $500 million aggregate principal amount of 5.050 percent senior notes due 2029 and $500 million aggregate principal amount of 5.650 percent senior notes due 2033 (together, the “Notes”). Autodesk intends to use the net proceeds from the sale of the Notes, together with cash on hand, to repay $1 billion aggregate principal amount under its existing term loan credit agreement. Wilson Sonsini Goodrich & Rosati advised Autodesk on the transaction.
Client Highlights
9.01.26
Firm Advises PMV Pharmaceuticals on Oversubscribed $50 Million Public Offering
On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.
Alerts
8.17.26
SEC Ends No-Action Responses Under Rule 14a-8
On August 14, 2026, the Division of Corporation Finance (the Division) of the U.S. Securities and Exchange Commission (the SEC or Commission) announced that, effective immediately, it will discontinue responding to no-action requests under Exchange Act Rule 14a-8.
Client Highlights
8.05.26
Wilson Sonsini Advises Rambus on Accelerated Share Repurchase Program
On August 5, 2026, Rambus Inc., a provider of industry-leading chips and silicon IP for data center and artificial intelligence (AI) infrastructure, announced that it initiated an accelerated share repurchase program with Mizuho Markets Americas LLC to repurchase an aggregate of $100 million of its common stock. Wilson Sonsini Goodrich & Rosati is representing Rambus in the transaction.